life sciences company Revive Therapeutics Ltd. RVVTF pushes his First phase I/II clinical trial of oral psilocybin for the treatment of methamphetamine use disorders while also developing one oral psilocybin thin film strip product.
Revive is currently investigating the potential of psilocybin as a treatment for addiction to this particular stimulant along with the University of Wisconsin-Madison. The phase I/II clinical trial includes both FDA and Institutional Review Board approvaland is under the direction of dr. Christopher Nicholas and Dr. Paul Hutson.
Clinical data is expected to provide further insight into the safety, efficacy and dosage of oral psilocybin and, if used, provide support future clinical trials for Revive’s novel oral psilocybin thin film strip product to be carried out in 2023.
The Company’s proprietary psilocybin product is being co-developed with the leading oral thin film pharmaceutical company LTS Lohmann Therapy Systems AG. Prototypes of the new creation have been developed and are currently being optimized for use in upcoming IND-enabled studies.
Revive uses its recently acquired Psilocin Pharma Corp. drive development a Psilocybin-based therapeutics pipeline for various health indications including mental illness, substance abuse and neurological disorders.
The company now owns one Cannabinoid Pharma Portfoliowhat to focus on rare inflammatory diseases. The FDA granted Revive orphan drug designation for the use of cannabidiol (CBD) to treat autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation.
Photo courtesy of Susie Hedberg and only_kim on Shutterstock.
